IXHL,Incannex Healthcare Limited | Healthcare

Healthcare

IXHL

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Incannex Healthcare LimitedIXHL

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

Market Cap

16.53M

Revenue (ttm)

98,000

Net Income (ttm)

-23.80M

Shares Out

27.55M

EPS (ttm)

-1.40

PE Ratio

n/a

Forward PE

n/a

Dividend

n/a

Ex-Dividend Date

n/a

Volume

31,570

Open

0.6000

Previous Close

0.5700

Day's Range

0.6000 - 0.6120

52-Week Range

0.4710 - 3.5500

Beta

2.13

Analysts

n/a

Price Target

n/a

Earnings Date

May 14, 2025

Description >

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies.

It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications.

The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol.

It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis.

In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials.

Incannex Hea

Latest News >

Coronavirus News highlights: Delta and Omicron variants spreading like 'tsunami', says TN health minister

Jan 5, 2022

Coronavirus Omicron India News LIVE Updates: The Indian Medical Association (IMA) requested the Centre and states to ensure that COVID duty of resident doctors do not exceed eight hours a day and after a week there should be a quarantine 10 to 14 day quarantine period in accommodation prescribed by the hospital. In the event of a Covid duty doctor falling ill, they should be hospitalised at the earliest. In a statement, the doctors' body said in case of untimely death, the status of COVID martyr and compensation as well as case-wise assistance should be arranged. There should also be a provision for taking care of the mental health of doctors, the IMA said. "Around 2,000 doctors died during the second wave of Covid. The mortality rate in the country was around 1.5 percent among the general population and around 2 to 3 percent among healthcare workers. According to this estimate, Covid occurred in about 1,00,000 doctors," the IMA said.

Funding Rundown: Reliance takes 26% stake in Dunzo for $200 mn, Bombay Shaving Company bags Rs 160 cr & Chalo eyeing $200 mn fundraise, says report

Jan 6, 2022

Here's a lowdown of the top deals from the startup space.

Australia agrees to delay Novak Djokovic's deportation; full hearing scheduled for January 10

Jan 6, 2022

World number one tennis player Novak Djokovic remained in Australia after his lawyers launched an appeal seeking to overturn the federal government decision. A court agreed not to deport him before a full hearing scheduled for Monday, leaving the Serbian champion holed up in a quarantine hotel in Melbourne for at least the next 72 hours.

India vs South Africa 2nd Test: SA win by 7 wickets, level series 1-1

Jan 6, 2022

South Africa defeated India by seven wickets in the second Test to level the three-match series 1-1 on Thursday. India's bowlers could not extract enough from the surface with Mohammad Shami getting the only wicket to fall on the day. The third and final Test begins in Cape Town from January 11.